EMA supports Sandoz’s Tysabri biosimilar amid various endorsements
The EMA’s decision marks a further step in the biosimilar’s pathway to potential approval and launch amid an ongoing legal battle.
The EMA’s decision marks a further step in the biosimilar’s pathway to potential approval and launch amid an ongoing legal battle.
What's Your Reaction?
